Kornimate/medical-research-clean huggingface dataset:
a study evaluating the efficacy and safety of inavolisib plus cdk4/6 inhibitor and letrozole vs placebo + cdk4/6i and letrozole in participants with endocrine-sensitive pik3ca-mutated, hormone receptor-positive, her2-negative advanced breast cancer

Conditions: Breast Cancer

Summary: this study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (cdk4/6i) and letrozole versus placebo plus a cdk4/6i and letrozole in the first-line setting in participants with endocrine-sensitive pik3ca-mutated hormone receptor-positive (hr+), human epidermal growth factor receptor 2-negative (her2-), advanced breast cancer (abc).


Eligibility criteria:
inclusion criteria: * women or men with histologically or cytologically confirmed carcinoma of the breast * documented er-positive and/or progesterone receptor-positive tumor according to american society of clinical oncology/college of american pathologists (asco/cap) guidelines * documented her2-negative tumor according to asco/cap guidelines * de-novo hr+ , her2- abc, or, alternatively, relapsed hr+ , her2- abc after at least 2 years of standard neoadjuvant/adjuvant endocrine therapy without disease progression during that treatment and disease-free interval of at least 1 year since the completion of that treatment * participants who have bilateral breast cancers which are both hr-positive and her2-negative * confirmation of biomarker eligibility * consent to provide fresh or archival tumor tissue specimen * measurable disease per response evaluation criteria in solid tumors, version 1.1 (recist v1.1) * eastern cooperative oncology group (ecog) performance status of 0 or 1 * adequate hematologic and organ function within 14 days prior to initiation of study treatment exclusion criteria: * pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required * metaplastic breast cancer * any prior systemic therapy for locally advanced unresectable or metastatic breast cancer * type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of type 1 diabetes * any history of leptomeningeal disease or carcinomatous meningitis * known and untreated, or active cns metastases. participants with a history of treated cns metastases are eligible * active inflammatory or infectious conditions in either eye or history of idiopathic or autoimmune-associated uveitis in either eye * symptomatic active lung disease * history of or active inflammatory bowel disease * any active bowel inflammation * prior hematopoietic stem cell or bone marrow transplantation * treatment with strong cytochrome p450 (cyp) 3a4 inhibitors or strong cyp3a4 inducers within 4 weeks or 5 drug-elimination half-lives, prior to initiation of study treatment
a study of using social networks to encourage three peers to complete screening for colorectal cancer

Conditions: Colon Cancer Screening

Summary: the black community has higher rates of colorectal cancer and lower rates of colorectal cancer screenings than whites. getting screened through fit testing may help catch colorectal cancer earlier, when it is easier to treat. msk has created a program to help people who have been fit tested to also help their peers (family, friends, and colleagues) in their community get fit tested. the researchers think that training people on peer outreach, such as telling people in your social network about fit testing and how to get it, may increase the rate of colorectal cancer screening. the purpose of this study is to see if training people on peer outreach increases the number of people who get screened for colorectal cancer through fit testing.


Eligibility criteria:
inclusion criteria: * self-identifies as black (inclusive of african, african-american, or afro-caribbean) * male * speaks english or french very well * is at least 45 years of age and no greater than 75 years of age * has completed fit testing within the prior year * has at least 5 close network affiliates, who are black males, and of at least 45 years of age and no greater than 75 years of age exclusion criteria: * has a household member who has already participated (or agreed to participate) * has already been approached by a peer participating in the study (index participant) to complete fit testing

Keywords: fecal immunochemical testing screening 23-078
freestyle libre monitoring in t2dm

Conditions: Type2diabetes

Summary: the goal of this clinical trial is to learn if blood sugar monitoring using a freestyle libre device can improve overall diabetes control in people with type 2 diabetes. the main questions it aims to answer are: * what is the effect of monitoring using the freestyle libre device for a period of 12 weeks on the blood sugar control of people with type 2 diabetes? * can monitoring using the freestyle libre device improve the quality of life of people with type 2 diabetes? participants will be asked to wear one of two brands of freestyle libre devices. in one group, participants will have 3 visits, while those in the second group, they will have 4 visits. researchers will compare the improvement in the sugar control for the individuals but also compare between the 2 groups.

this is a prospective, randomised, open-labelled, non-ctimp, pilot study. participants meeting the inclusion criteria and who have consented to participate in the study will be randomised on a 1:1 ratio to receive either libre 2 or libre pro iq. randomisation will be carried out using an online randomisation tool to allocate a participant to a treatment group. the study will consist of three visits (libre 2 arm) and four visits (libre pro iq arm). the study will be completed over 12 weeks.

Eligibility criteria:
inclusion criteria: * males and females living with type 2 diabetes mellitus (t2dm) who are aged ≥ 18 and ≤ 75 years * on one or more non-insulin glucose lowering agent(s) * hba1c ≥ 69 mmol/mol * able to provide written informed consent exclusion criteria: * participants with a life expectancy of less than 1 year * participants with cognitive dysfunction or neurological disorder, which will interfere with regular, flash glucose monitoring * participants with chronic kidney disease (ckd) with egfr \< 45ml/min/1.73m2 or decompensated liver disease or decompensated congestive cardiac failure * myocardial infarction in the preceding 3 months or if percutaneous coronary intervention planned in the next 6 months * participants on supra-physiological doses of steroids, for example, prednisolone for the treatment of rheumatoid arthritis * participants on active dialysis or planned for dialysis treatment during the study * currently participating in another device or drug study that could affect glucose measurements or management * women who are pregnant, breastfeeding or planning to become pregnant. women should use a reliable form of contraception throughout the study * participants who are already using continuous glucose monitoring (cgm) * participants who have pacemakers, implanted cardioverter defibrillator devices or neurostimulators * participants with an allergy to medical grade adhesive * a blood transfusion in the preceding 3 months or a planned blood transfusion during the course of the study
healthy planet hepatitis b

Conditions: Hepatitis B

Summary: this quality improvement project utilizes epic health planet to increase screening for chronic hepatitis b through the creation of registries and ordering of hepatitis b laboratory panels.


Eligibility criteria:
inclusion criteria: - asian ancestry as determined by ethnicity/race, primary language, surname as recorded in the electronic health record exclusion criteria: - previously completed hepatitis b screening tests
muscle assessment in women who have undergone roux-en-y gastric bypass surgery

Conditions: Muscle Function, Handgrip Strength Test

Summary: the purpose of this study is to assess muscle function in women at least two years after being submitted to roux-en-y gastric bypass surgery and compare with a control group

obesity is a public health problem globally. according to the world health organization (who) estimated are 600 million obese worldwide and according to national health survey 2010 in chile 67% of the population suffers from some degree of overweight having approximately 300,000 morbidly obese. the first-line treatment for obesity is diet, exercise and cognitive behavioral therapy, however, these interventions are not effective enough to control long-term obesity, and so bariatric surgery is currently the treatment of choice to control morbid obesity. overall, after bariatric surgery, most patients lose on average 60% of excess weight and improve their comorbidities during the first postoperative year, however, the long term effects of this weight reduction are not known in detail regarding body composition and muscle function. the aim of this study is to assess muscle function measured by hand grip strength test in women at least 2 years after bariatric surgery (roux-en-y gastric bypass) and to compare with control group.

Eligibility criteria:
inclusion criteria: case group: women, 18-70 y, submitted to a roux-en-y gastric bypass surgery at least two years ago exclusion criteria: * osteoarthritis of hands and knees, any osteoarticular, rheumatologic or neurological disease hindering the performance of the tests of muscle function; type 2 diabetes mellitus; acute infectious diseases; use of muscle relaxants; physical and intellectual disabilities and uncontrolled hypothyroidism.

Keywords: bariatric surgery, sarcopenia
patient specific induced pluripotency stem cells (psips)

Conditions: Hepatic Disorders; Eye Disorders

Summary: induced pluripotent stem cells (ipscs) are adult cells that have been genetically reprogrammed to an embryonic stem cell-like state by being forced to express genes and factors important for maintaining the defining properties of embryonic stem cells. the reprogramming of adult cells into embryonic stem (es) cells enables the generation of patient-specific stem cells and thus has enormous potential for the treatment and analysis of degenerative diseases. in this project the investigators are going to induce pluripotent stem cells from cell cultures from skin biopsies of patients. the ips cells will be developed for modeling diseases and drug discovery as well as basic research.

ips cells are typically derived by transfection of certain stem cell-associated genes into non-pluripotent cells, such as adult fibroblasts. transfection is typically achieved through viral vectors, such as retroviruses. transfected genes include the master transcriptional regulators oct-3/4 (pouf51) and sox2, although to enhance the efficiency of induction some other genes e.g. klf4, c-myc. in this study after separation the fibroblasts from patient's skin biopsy, the cells are transfected with 4 yamanaka factors (human oct4, sox2, klf4, c-myc) after 3-4 weeks, transfected cells are isolated through morphological selection.

Eligibility criteria:
inclusion criteria: * donors suffering from different (specified) metabolic disorders * donors suffering from different (specified) eye disorders which resulted to blindness * special blood group: o bombay exclusion criteria: * none

Keywords: induced pluripotent stem cells hepatic disorders eye disorders blood groups
transoral removal of specimen during laparoscopic gastric resection

Conditions: Gastric Disease; Bariatric Surgery Candidate

Summary: investigators aimed to present the patients who underwent laparoscopic gastrectomy with transoral specimen extraction.

minimally invasive surgical procedures such as nose (natural orifice spesmen extraction) and notes (natural orifice translumenal endoscopic surgery) are gradually increasing. the transoral way is probably the least used for nose.

Eligibility criteria:
inclusion criteria: * laparoscopic gastric resection * patients aged 18-70 years exclusion criteria: * other transorally removed organs (appendix, gallbladder, surrenal)
development of a scoring and prediction model for weaning success in ards patients using ventilation parameters combined with artificial intelligence and deep learning techniques

Conditions: Deep Learning; Artificial Intelegence; ARDS (Acute Respiratory Distress Syndrome)

Summary: this study aims to develop an ai-supported scoring model to optimize the weaning processes of ards patients from mechanical ventilation. retrospective analysis will be conducted on the data of 25,000 patients, focusing on ventilator parameters and hemodynamic variables. the model will be designed to contribute to clinical decision support systems.

the aim of this study is to develop an artificial intelligence and deep learning-supported scoring system using ventilator parameters obtained during the mechanical ventilation process in patients diagnosed with ards. this system seeks to predict and optimize the weaning process, facilitating successful liberation from mechanical ventilation. in this context, our study will analyze data from 25,000 patients obtained from the metavision system. from this data pool, ards patients will be filtered and divided into two groups: those successfully weaned from mechanical ventilation (weaned) and those who were not (non-weaned). the ventilator parameters of both groups, including oxygenation indices, driving pressure, and total mechanical power, will be examined in detail. the collected data will be analyzed using artificial intelligence and deep learning algorithms to develop a scoring system capable of predicting patients' weaning processes. this system is designed to guide clinicians in patient management and enhance the success of weaning procedures. the results of this study aim to contribute to more efficient and safer management of the weaning process for ards patients. furthermore, the implementation of ai-supported scoring systems in intensive care units is expected to promote widespread adoption and improve the quality of patient care.

Eligibility criteria:
inclusion criteria: * ards diagnosis * aged 18 years and older * intubated and followed by mechanical ventilation * admission on intensive care unit * complete data on clinical support and desicion system exclusion criteria: * missing data * under 18 years of age * followed by non-ards conditions * terminal status

Keywords: deep learning
metformin in obese children and adolescents

Conditions: Obesity; Insulin Resistance

Summary: the purpose of this study is to determine whether metformin is effective in reducing bmi and insulin resistance in obese children and adolescents.

the prevalence of obesity in children and adolescents is increasing rapidly and is associated with significant medical and psychosocial consequences persisting into adulthood. obesity may lead to metabolic complications, such as insulin resistance, which can progress via impaired fasted glucose and impaired glucose tolerance to type 2 diabetes mellitus (t2dm) and to the development of micro- and macro-vascular complications. metformin, an oral anti-diabetic licensed for t2dm for adults and children from 10 years onwards, is already used off label in obese children and adolescents with insulin resistance, even though the specific effects of metformin in these obese children and adolescents have not been elucidated, particularly upon long-term use. the rationale for this study is based on the hypothesis that metformin may reduce body mass index (bmi), insulin resistance and percentage of body-fat in obese children and adolescents with insulin resistance. further more it is anticipated that metformin may delay the progression to t2dm and thereby micro- and macro-vascular complications in obese children and adolescents with insulin resistance.

Eligibility criteria:
inclusion criteria: * age ≥ 10 and ≤ 16 years at study entry * caucasian descent * obesity defined as bmi-sds \> 2.3 * insulin resistance defined as homa-ir ≥ 3.4. * an obtained informed consent from subjects and parents/caregivers. exclusion criteria: * presence of t2dm (american diabetes association criteria) * presence of endocrine disorders with steroid therapy * suspicion of polycystic ovarium syndrome; * height \< -1.3 sd of target height; * syndrome disorders with or without mental retardation; * use of anti-hyperglycaemic drugs; * pregnancy (pregnancy test will be performed, if applicable); * (history of) alcohol abuse; * impaired renal and/or hepatic function (defined as gfr \ 150% of normal value for age); * use of ritonavir; use of ace inhibitors; * insufficient knowledge of the dutch language.

Keywords: obesity children adolescents metformin insulin resistance
effects of spencer's technique on shoulder function

Conditions: Shoulder

Summary: the purpose of this study is to see the impact of a modified spencer's technique on tissue stiffness, mobility, and blood flow of the shoulder joint. spencer's technique is a well-known osteopathic manipulative treatment (omt) that is common for treating adhesive capsulitis and is believed to help blood flow. there are studies that look at the clinical effects of the technique and/or compare it to other techniques; however, measuring the extent to which spencer's technique, or this modified technique, improves tissue stiffness and blood flow has never been written in the literature. this study will serve as a proof of concept that this technique improves tissue stiffness, blood flow, and mobility of the shoulder join as well as the nearby areas. using ultrasound, the investigators will measure tissue stiffness and blood flow and will analyze the mobility of the shoulder joint using a vicon motion capture system.


Eligibility criteria:
inclusion criteria: • male and female subjects 18-50 years old exclusion criteria: * prior shoulder surgery or injury to the reported dominant throwing arm * shoulder pain in the reported dominant throwing arm within the last 6 months * diagnosis cervical radiculopathy or pinched nerve in the neck * connective tissue or muscle disorders * known pregnancy * tobacco use * known diabetes or prediabetes * allergy to ultrasound gel (propylene glycol)

Keywords: osteopathic physicians shoulder diagnostic imaging motion capture range of motion, articular blood circulation pain
strategy for adequate blood pressure lowering in the patients with intracranial atherosclerosis

Conditions: Brain Ischemia

Summary: to develop adequate blood pressure (bp) lowering strategy after subacute ischemic stroke patients with symptomatic severe intracranial atherosclerosis. primary hypothesis of this study is that aggressive bp control (lowering systolic bp between 110mmhg and 120mmhg) will not increase the ischemic lesion volumes in hemisphere compared to modest bp lowering (lowering systolic bp between 130mmhg and 140mmhg) in the patients with symptomatic severe intracranial atherosclerosis.

the benefits of bp lowering in the prevention of primary and secondary prevention of stroke is established well, although absolute target bp level is uncertain. current guidelines defined the normal bp as \<120/80mmhg and recommend individualized target bp level. large well performed stroke prevention trials consistently showed that reduction of 10/5mmhg in patients with systolic bp below 140mmhg had clear benefits in the prevention of cardiovascular events. however, we have a dilemma about bp control in the patients with severe intracranial atherosclerosis. aggressive bp control will be more effective in the prevention of overall cardiovascular events than modest bp control, but aggressive bp control will reduce cerebral perfusion in the territory of severe intracranial disease and may increase the risk of ischemic damage. the study will try to reveal aggressive bp control in the patients with symptomatic severe intracranial atherosclerosis is not increase ischemic lesion volume in hemisphere to compare modest bp control.

Eligibility criteria:
inclusion criteria: * acute symptomatic ischemic stroke having relevant lesion on dwi(diffusion weighted image) mri 7 days after and 42 days within onset. * relevant stenosis(more than 50%) or occlusion from mca(middle cerebral artery)(m1) to distal of ica(internal carotid artery ) on mr(magnetic resonance) angiogram or ct angiogram. * mean systolic blood pressure\>=140mmhg or taking antihypertensive drug on screening. exclusion criteria: * taking more than 3 antihypertensive drugs and mean systolic blood pressure\>=150mmhg on screening. * history of recent thrombolysis but stenosis or occlusion remained after thrombolysis. * evidence of orthostatic hypotension * suspicious embolic cerebrovascular stenosis * planned state of cerebrovascular surgery or angioplasty or stent 7 months within screening. * severe stroke-nihss\>=16 * mean systolic blood pressure\>=200mmhg which is not able to control on screening. * abnormal blood test finding (abnormal lft(liver function test), anemia, renal insufficiency) * pregnant or breast-feeding * severe stroke sequela or medical problem * suspicious secondary hypertension * disease causing edema or significant ankle edema on screening. * severe heart failure which correspond to nyha (new york heart association )heart failure classification class iii or iv. * inappropriate condition determined by investigator * patient who do not have flair image on or two months prior to screening.

Keywords: blood pressure atherosclerosis brain ischemia
a trial of echinacea in children

Conditions: Common Cold

Summary: this is a randomized trial to determine if echinacea is effective in shortening the length and/or lessening the severity of colds in children 2 through 11 years old.

upper respiratory tract infections (uri's) are a significant health burden in childhood. uri's are a major reason for visits to health care providers, and up to 35 percent of young children at any given time are taking some over-the-counter cold medication. unfortunately, data suggest that most of these medications have limited effectiveness. alternative medical therapies are growing in popularity; in a recent survey of parents of children being seen by pediatricians in seattle, washington, 24.2 percent indicated that their child had been seen by an alternative medicine health care provider, and 53.3 percent received therapies for the treatment of uri's in children. the proposed study is a randomized, double blind, placebo controlled trial of echinacea for the treatment of uri's in children 2-11 years old. the aims of the project are: to determine if echinacea shortens the duration and/or lessens the severity of uri's, if children receiving echinacea for treatment of uri's have a reduced rate of secondary bacterial infections, and to determine if the use of echinacea in patients 2-11 years old is associated with any significant side effects. a two-year study of 600 children is planned. not only will the results of this study determine if echinacea, the most popular medicinal herb sold in the united states, is an effective therapy for uri's in children, the study will provide a design framework for further assessment on the efficacy of other complementary and alternative medicines in children.

Eligibility criteria:
inclusion criteria: * parent available to observe child during the night * parent peaks and reads english exclusion criteria: * history of asthma or allergic rhinitis * history of auto-immune disease * history of chronic lung disease * allergy to sunflower species